Connect with us
European Gaming Congress 2024

Artificial Intelligence

Ability Biologics Announces the Closing of its US $18 Million Seed Funding Extension toward the Generation of Novel, Highly Targeted Immunomodulators

Published

on

ability-biologics-announces-the-closing-of-its-us-$18-million-seed-funding-extension-toward-the-generation-of-novel,-highly-targeted-immunomodulators

MONTREAL, June 18, 2024 /PRNewswire/ — Ability Biologics (“Ability”) announced the final closing of its seed funding, raising a total of $18 million (US), a financing round led by founding investor Amplitude Ventures (“Amplitude”). Amplitude is joined by the Fonds de solidarité FTQ, Investissement Québec, Charles River Laboratories, Theodorus and Alexandria Venture Investments. Ability, a pioneer in the application of generative Artificial Intelligence (AI) to therapeutic discovery, focuses its platform on discovering and developing potent and selective antibody therapeutics for cancer and immune-related disorders. Ability Biologics, through its AbiLeap™ discovery engine, is generating novel, logic-enabled antibodies with the potential to become best-in-class or first-in-class therapeutics.

Ability’s leadership team combines deep experience in immunology, antibody discovery, engineering and therapeutic development, from the bench to commercial stage, and is leveraging this experience to create next generation antibodies using powerful computational tools through its unique, proprietary AI platform. The AbiLeap™ discovery engine is an AI platform built on top of one of the largest databases of antibody-antigen interactions ever constructed, bringing together more than five years of discovery data and incorporating both public and private data sources. AbiLeap™ allows Ability to address a longstanding challenge by generating fully human antibodies that are logic-gated, enabling them to target specific tissues and cells based on the local microenvironment, including conditions such as secondary antigens, pH, temperature and/or the presence of specific metabolites.
“We’re seeing a need for a new generation of antibodies and modalities as simply binding, blocking or agonizing a single receptor is not enough to achieve therapeutic impact,” said Giles Day, Co-founder and CEO of Ability. “At Ability, our platform overlays multiple approaches in a single molecule, enhancing specificity and selectivity to develop potent therapeutics with broad therapeutic windows. To do so, our antibodies employ tried and tested IgG formats that enable easier manufacturing, storage and administration, avoiding complex formats that introduce multiple risks from manufacturing to immunogenicity,” concluded Giles Day.
“We are focused on solving the next set of complex biology challenges and one of them is to tackle the issue of on-target, off-tissue toxicity, which is limiting the utility of antibody therapy,” said Dion Madsen, CFA, Co-founder and Partner at Amplitude Ventures. “Ability’s proprietary platform stands out as an intelligent way of rapidly developing selective and potent, ultra-targeted biotherapeutics to enhance potency and patient outcomes.”
“The life science and biotech sector is in constant flux, and we are proud to provide financial backing for Ability’s ongoing innovations,” said Bicha Ngo, President and CEO of Investissement Québec. “Harnessing the latest technologies, like artificial intelligence, in the development of antibodies will solidify Québec’s expertise in an area that is critical to the treatment of various types of cancer, and ultimately other diseases, that affect many Quebecers every year.”
About Ability Biologics
Ability Biologics is the premier cell targeting company. Its powerful AbiLeap™ discovery engine combines massively parallel, continuously learning AI with an extensive database of antigen-antibody interactions to generate fully human, IgG-based multi-specific antibodies of exquisite selectivity and affinity. The antibodies respond to environmental signals within the cellular microenvironment, generating logic-gated therapeutics. Ability is dedicated to developing the most potent and selective antibody therapeutics for areas of great unmet need. To learn more, visit ability.bio, our linkedin page or contact us at [email protected].
About Amplitude Ventures
Amplitude is a full-stack venture capital firm using a unique growth model to build companies with world-class management teams and scale companies to breakout potential. With over $500 million under management and offices in Montreal, Toronto and Vancouver, Amplitude applies a proven, evidence-based approach to investing in leading precision medicine companies. Learn more about Amplitude and its Pre-Amp venture studio at amplitudevc.com.
About the Fonds de solidarité FTQ
The Fonds de solidarité FTQ is a source of pride in Québec, fulfilling its mission through a unique business model created 40 years ago. Since then, the Fonds has rallied Québec into action thanks to the retirement savings of over 769,000 shareholders. With net assets of $18.9 billion as at November 31, 2023, the Fonds supports more than 3,700 companies through venture and development capital investments based on the belief that impact is created as much by financial as social returns. For more information, visit fondsftq.com.
About Investissement Québec
Investissement Québec’s mission is to play an active role in Quebec’s economic development by stimulating business innovation, entrepreneurship, and business acquisitions, as well as growth in investment and exports. Operating in all the province’s administrative regions, the Corporation supports the creation and growth of businesses of all sizes with investments and customized financial solutions. It also assists businesses by providing consulting services and other support measures, including technological assistance available from Investissement Québec Innovation. In addition, through Investissement Québec International, the Corporation prospects for talent and foreign investment, and assists Quebec businesses with export activities. For more information, visit investquebec.com.
About Theodorus
Theodorus is a venture capital fund targeting mainly high-potential spin-offs coming from the “Université Libre de Bruxelles” (ULB), though also open to all innovative ventures in life sciences. The fund invests primarily in early-stage biotechnology, medical technology and healthcare technology companies that have developed disruptive innovations. In addition to its financial role, Theodorus is actively involved in developing its portfolio companies and seeing them through to success. Today, Theodorus manages over $100 million in assets that have supported more than 40 businesses. Theodorus has offices in Montreal and Brussels. For more information, visit theodorus.be.
Media Contact: Philippe Périou Communications-Marketing, [email protected], +1 450.831.4414 (GMT – 4h)
Photo – https://mma.prnewswire.com/media/2440998/Ability_Biologics_Ability_Biologics_Announces_the_Closing_of_its.jpgLogo – https://mma.prnewswire.com/media/2440997/Ability_Biologics_Ability_Biologics_Announces_the_Closing_of_its.jpg

View original content:https://www.prnewswire.co.uk/news-releases/ability-biologics-announces-the-closing-of-its-us-18-million-seed-funding-extension-toward-the-generation-of-novel-highly-targeted-immunomodulators-302175055.html

Continue Reading
Advertisement
Stake.com

Artificial Intelligence

Huawei Yang Chaobin: AI for Networks Powers Productivity

Published

on

huawei-yang-chaobin:-ai-for-networks-powers-productivity

SHANGHAI, June 26, 2024 /PRNewswire/ — At MWC Shanghai 2024, Huawei’s Board Member and President of ICT Products & Solutions Yang Chaobin discussed how AI technology, particularly generative AI, brings new opportunities and requirements to telecom networks. He also discussed the importance of integrating and applying innovative digital and intelligent technologies to accelerate network evolution towards higher-level autonomy and make networks more productive.

In his speech entitled “AI for Networks: Powering Productivity”, Yang said, “The telecom industry has kicked off 5G-A, while generative AI has achieved major breakthroughs. AI, as a foundational technology for network automation, is set to accelerate the industry’s transition towards higher-level network autonomy, and play a key role in 5G-A business success.”
Yang also noted that generative AI is transforming information production, processing, transfer, and exchange to create mobile AI opportunities and boost traffic, connections, and services. This also means higher requirements for differentiated service experience monetization and automated network O&M. Yang introduced how Huawei’s upgraded Autonomous Driving Network (ADN) solution is now powered by the company’s Telecom Foundation Model to provide five role-based copilots and five scenario-based agents. The solution will enhance the value of networks in three aspects: service enablement, network maintenance, and experience assurance.
According to Yang, the copilots can support five roles: network operations center (NOC) staff, customer service personnel, field maintenance engineers, home broadband installation and maintenance engineers, and home broadband users. The copilots can reshape human-machine interaction and collaboration by supporting intelligent knowledge Q&A and assisted O&M, significantly improving efficiency and lowering the bar for technical engineers.
Furthermore, the agents can support five high-value scenarios across network maintenance, optimization, and operation. Based on preset policies, the agents can automatically break down complex tasks, orchestrate processes, and invoke tools and application programming interfaces (APIs) to achieve scenario-based autonomy, greatly improving both operational efficiency and customer experience.
The copilots and agents highlight the business value that AI can create in innovative applications. During his keynote, Yang shared some typical scenarios in which the copilots and agents can create great value, including fault management, wireless network optimization, and enterprise campus private networks.
MWC Shanghai 2024 will be held from June 26 to June 28 in Shanghai, China. During the event, Huawei will showcase its latest products and solutions at stands E10 and E50 in Hall N1 of the Shanghai New International Expo Centre (SNIEC).
2024 will mark the first year of commercial 5.5G, and F5.5G gigabit optical network deployment has already begun. Synergies across networks, cloud, and intelligence are set to give rise to pervasive intelligent applications and increasingly diverse user experiences. Together with global operators, industry professionals, and opinion leaders, Huawei will dive into exciting topics at this year’s MWC Shanghai, like how to amplify 5G’s success in the 5.5G era and how to tap into the potential of operator revenue growth to bring us even faster to the intelligent world. For more information, please visit: https://carrier.huawei.com/en/events/mwcs2024.
Photo – https://mma.prnewswire.com/media/2448914/Huawei.jpg

View original content:https://www.prnewswire.co.uk/news-releases/huawei-yang-chaobin-ai-for-networks-powers-productivity-302183438.html

Continue Reading

Artificial Intelligence

Medasense Announces a Strategic Agreement With Global Medical Company, Nihon Kohden Corporation

Published

on

medasense-announces-a-strategic-agreement-with-global-medical-company,-nihon-kohden-corporation

RAMAT GAN, Israel, June 26, 2024 /PRNewswire/ — Medasense, a global leader in pain monitoring solutions, is proud to announce a strategic partnership with Nihon Kohden for the exclusive distribution of its revolutionary pain monitoring device in Japan. This partnership is intended to transform pain management practices across Japanese healthcare facilities, offering a significant advancement in patient care.

 
Nihon Kohden, renowned for its history of excellence in providing innovative high quality, reliable medical technology that improves the way healthcare is practiced, is partnering with Medasense to introduce its nociception monitor to the Japanese market. This cutting-edge device, with its state-of-the-art AI powered NOL – Nociception Level Index®, provides real-time, objective pain monitoring, enabling the personalization and optimization of pain treatment. It will be accessible to hospitals and clinics throughout Japan through Nihon Kohden’s extensive distribution channels pending regulatory approval.
Medasense’s CEO & Founder, Galit Zuckerman, expressed enthusiasm about the collaboration: “We are honored to partner with Nihon Kohden, a company with a long history of excellence, that shares our vision of improving patient care through innovative solutions. Our mission is to help all patients suffer less from pain and the adverse effects of pain medication. Nihon Kohden’s established clinical, technological leadership and expertise in the Japanese market make them the perfect partner to distribute our nociception monitor.”
NOL monitoring provides an AI powered, clinically validated index to objectively quantify the physiological response to pain (nociception) supporting clinicians in delivering personalized anesthesia tailored to patient requirements. With over 40 peer reviewed publications, clinical studies have demonstrated that NOL-guided analgesia resulted in intraoperative opioid sparing, and improved post operative pain scores and patient recovery.1,2
For more information about Medasense and Nihon Kohden, please visit www.medasense.com and www.nihonkohden.com/.
About Medasense and NOL – Nociception Level Index® Technology
Medasense is transforming pain management with its breakthrough technology that empowers clinicians to optimize and personalize pain control, significantly reducing the risk of pain or of overmedication. The company’s flagship product, the PMD-200™, equipped with the NOL-Nociception Level Index®, leverages advanced artificial intelligence and a proprietary non-invasive sensor system. This unique platform provides objective monitoring and quantification of a patient’s pain response, making it an essential tool in an operating room and critical care unit settings where patients cannot communicate their pain levels. The PMD-200 is the first and only monitor to be authorized by the FDA for pain measurement for anaesthesiology. It has been used in over 100,000 surgeries worldwide, and is commercially available in the US, Europe, Canada, Latin America and Israel.
Watch Medasense’s 1-minute video
About Nihon Kohden
Founded in 1951, Nihon Kohden is a global leader of medical solutions with the goal to improve healthcare with advanced technology. For more than 70 years, Nihon Kohden has continued to provide a wide range of medical electronic equipment including EEG, EMG/EP measuring systems, electrocardiographs, bedside monitors, defibrillators, AEDs, ventilators, and hematology instruments.
Nihon Kohden utilizes cutting-edge technology to support medical treatment in all clinical areas, integrating medical devices into the IT network to meet customers’ requirements and offers a wide, comprehensive solution.
For further information please contact:Rachel Weissbrod, VP Clinical & Market Development, [email protected] 
1.  Meijer, F., Honing, M., Roor, T., Toet, S., Calis, P., Olofsen, E., Martini, C., van Velzen, M., Aarts, L., Niesters, M., Boon, M., Dahan, A. (2020). Reduced postoperative pain using Nociception Level-guided fentanyl dosing during sevoflurane anaesthesia: a randomised controlled trial. British Journal of Anaesthesia, In Press. DOI:https://doi.org/10.1016/j.bja.2020.07.057
2.  Fleur S. Meijer, Chris H. Martini, Suzanne Broens, Martijn Boon, Marieke Niesters, Leon Aarts, Erik Olofsen, Monique van Velzen, Albert Dahan. Nociception-guided versus Standard Care during Remifentanil–Propofol Anesthesia: A Randomized Controlled Trial. Anesthesiology (2019); 130:745–755
Logo: https://mma.prnewswire.com/media/1169999/Medasense_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/medasense-announces-a-strategic-agreement-with-global-medical-company-nihon-kohden-corporation-302183281.html

Continue Reading

Artificial Intelligence

IoT Sensors Market Set to Surpass USD 107.74 Billion by 2031| SkyQuest Technology

Published

on

iot-sensors-market-set-to-surpass-usd-107.74-billion-by-2031|-skyquest-technology

WESTFORD, Mass., June 26, 2024 /PRNewswire/ — According to SkyQuest, the global IoT Sensors Market size was valued at USD 11.20 Billion in 2022 and is poised to grow from USD 14.40 Billion in 2023 to USD 107.74 Billion by 2031, at a CAGR of 28.60% during the forecast period (2024-2031).

IoT sensors are sensors that are specifically designed for Internet of Things (IoT) devices and applications. High adoption of IoT devices and growing advancements in IoT technologies are fostering demand for novel IoT sensors. The global IoT sensors market is segmented into sensor type, vertical, and region.
Download a detailed overview:
https://www.skyquestt.com/sample-request/iot-sensors-market
IoT Sensors Market Overview: 
Report Coverage 
Details 
Market Revenue in 2023 
$ 14.40 billion 
Estimated Value by 2031 
$ 107.74 billion 
Growth Rate 
Poised to grow at a CAGR of 28.60% 
Forecast Period 
2024–2031 
Forecast Units 
Value (USD Billion) 
Report Coverage 
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends 
Segments Covered 
Sensor Type, Network Technology, and Vertical
Geographies Covered 
North America, Europe, Asia Pacific, Middle East & Africa, Latin America
Report Highlights 
Updated financial information / product portfolio of players 
Key Market Opportunities 
Proliferation of Smart Devices
Key Market Drivers 
Advancements in Wireless Communication Technologies
Segments covered in IoT Sensors Market are as follows:
Sensor TypeTemperature Sensor, Pressure Sensor, Humidity Sensor, Flow Sensor, Accelerometer, Magnetometer, Gyroscope, Inertial Sensor, Image Sensor, Touch Sensor, Proximity Sensor, Acoustic Sensor, Motion Sensor, Occupancy Sensor (Image Processing Occupancy Sensors, Intelligent Occupancy Sensors), CO2 Sensor, Other Sensors (Light sensor, Radar sensor)Network TechnologyWired (KNX, LonWorks, Ethernet, MODBUS, DALI), Wireless (Wi-Fi [Bluetooth Smart, Wi-Fi Bluetooth Smart, Bluetooth Smart / Ant+, Bluetooth 5]), ZIGBEE, Z-WAVE, NFC, RFID, ENOCEAN, THREAD, GLoWPAN, WIRELESS-HART, Frocess field bus, DECT-ULE, Others (ANT+, ISA100, GPS, Sub-Gig, and Cellular)VerticalConsumer (Home automation, Smart cities, Wearable electronics), Commercial (Retail, Aerospace and Defense, Logistics and supply chain, Entertainment, Financial Institutes, Corporate Offices), Industrial (Energy, Industrial Automation, Transportation, Healthcare, Smart agriculture)Request Free Customization of this report:
https://www.skyquestt.com/speak-with-analyst/iot-sensors-market
Pressure Sensors Keeping Up the Pressure in IoT Sensors Market
Pressure sensors are used in cars as well as industrial facilities used to make cars and are a vital part of almost all kinds of technical devices or products. Pressure sensors play a vital role in maintaining the safety of multiple operations by keeping the pressure in check and warning users when it reaches unsafe levels. High emphasis on security around the world is projected to promote the demand for pressure sensors in the future. Aerospace, healthcare, and manufacturing are some key industry verticals where demand for pressure sensors will always be high.
The rapid surge in the use of gesture-sensitive devices all over the world is promoting the demand for accelerometer sensors. From factory automation to smart homes, the use of accelerometer sensors is projected to soar high over the coming years. Rising sales of fitness trackers and gaming consoles are also estimated to bolster the demand for accelerometer sensors in the future.
Temperature sensors are also anticipated to be highly popular in multiple IoT devices owing to the surging demand for temperature monitoring and control in various applications. Temperature sensors are also highly vital in maintaining the safety of IoT devices and surroundings to avoid mishaps due to excessive increases or drops in temperatures. Other types of sensors include motion sensors, light sensors, CO2 sensors, occupancy sensors, gyroscopes, proximity sensors, etc. All these different types of sensors are highly crucial for sustained IoT sensors market growth across the forecast period and beyond, therefore investing in any of these could help market players bolster their share.
View report summary and Table of Contents (TOC):
https://www.skyquestt.com/report/iot-sensors-market
High IoT Adoption Allows Industrial Vertical to Take Crown in Revenue Generation
The use of IoT technologies in the industrial vertical is increasing rapidly, which is why this sub-segment holds prominence in the global IoT sensors market. High demand for automation and increasing use of IoT devices to achieve the same are slated to foster new opportunities for IoT sensors market players in this segment. High adoption of the Industry 4.0 trend is also helping this sub-segment boost the demand for IoT sensors. Development of smart infrastructure is also boosting the demand for IoT sensors in the commercial vertical. From healthcare to construction, multiple industry verticals are promoting the use of IoT technologies and thereby driving sales of IoT sensors as well.
Pressure sensors for IoT devices and IoT sensors for industrial verticals are projected to be highly popular. IoT sensor companies should invest in these sub-segments to get the best return on their investments. Meanwhile, new companies can experiment with other segments to find what suits the best for their business and focus on the same. As per analysts, investing in the development of novel proximity and accelerometer sensors will be highly rewarding for upcoming IoT sensor companies.
Related Reports:
Sensor Market
Internet Of Things (IoT) Market
Internet Of Things (IoT) Professional Services Market
IoT Security Market
5G IoT Market
About Us:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.
We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization has expanded our reach across North America, Europe, ASEAN and Asia Pacific. 
Contact:Mr. Jagraj SinghSkyQuest Technology1 Apache Way,Westford,Massachusetts 01886USA (+1) 351-333-4748Email: [email protected] Our Website: https://www.skyquestt.com/
Logo: https://mma.prnewswire.com/media/2446095/SkyQuest_Logo.jpg 
 

View original content:https://www.prnewswire.co.uk/news-releases/iot-sensors-market-set-to-surpass-usd-107-74-billion-by-2031-skyquest-technology-302183053.html

Continue Reading

Trending